Streetbeat News

Regulatory

MGRX

Mangoceuticals, Inc. (NASDAQ:MGRX) has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing. The company's stock maintained a closing bid price of at least $1.00 for 10 consecutive business days.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:40 pm

SPY

The Core PCE Price Index for September increased by 2.7% year-over-year, slightly above the estimated 2.6%. This indicates a modest rise in inflation, which could influence market expectations regarding interest rates and economic growth.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:30 pm

SRRK

Scholar Rock will present new clinical and biomarker data from the Phase 1 DRAGON trial at the SITC 39th Annual Meeting. The presentation will include safety, efficacy, and biomarker data for SRK-181 in patients with advanced solid tumors.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:24 pm

APLI

Appili Therapeutics shares rose following the company's announcement of alignment with the FDA on development requirements for its ATI-1801 topical antiparasitic product.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:23 pm

TSLA

Tesla plans to expand its 'Actually Smart Summon' feature to Europe, China, and other regions, following its U.S. release. The feature allows Tesla cars to be summoned to specific locations via the Tesla app. The company also plans to roll out its full self-driving software in Europe and China by Q1 2025, pending regulatory approval.

Portfolio Pulse from Anan Ashraf

October 31, 2024 | 12:22 pm

AEE

Ameren Missouri, a subsidiary of Ameren Corporation, has received approval to build an 800MW natural gas energy center, Castle Bluff, expected to be operational by 2027. This $900 million investment aims to provide reliable backup energy, complementing renewable sources.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:19 pm

LPCN

Lipocine Inc. has entered into a distribution and license agreement with SPC Korea to commercialize TLANDO in South Korea. Lipocine will receive upfront, regulatory, and sales milestone payments, as well as royalties on net sales.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:12 pm

GLD

NEM

Newmont seeks to extend the permit for its Cadia mine in Australia until 2050, which would provide significant regional economic benefits and align with sustainability goals. The extension is under review by the NSW Department of Planning.

Portfolio Pulse from Stjepan Kalinic

October 31, 2024 | 11:53 am

BITW

XRP

The cryptocurrency industry is optimistic about a favorable regulatory environment post-U.S. presidential elections, regardless of the winner. Both candidates, Trump and Harris, are seen as potentially supportive of crypto innovation. Industry leaders, including Bitwise and Ripple, are preparing for policy shifts that could benefit the sector.

Portfolio Pulse from Benzinga Neuro

October 31, 2024 | 11:50 am

KPTI

Karyopharm Therapeutics has announced a change in the co-primary endpoint of its Phase 3 SENTRY trial, replacing TSS50 with Abs-TSS, following FDA feedback. The trial will also increase its sample size to 350 patients, with top-line data expected in the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:43 am